Franco Valle
Director of Finance/CFO at BIOMEA FUSION, INC.
Net worth: 447 100 $ as of 31/05/2024
Profile
Franco Valle's current job is as the Chief Financial & Accounting Officer at Biomea Fusion, Inc. Mr. Valle's former jobs include being a Senior Director-Accounting at Pharmacyclics LLC, a Controller at Iovance Biotherapeutics, Inc. from 2017 to 2018, a Principal Accounting Officer & SVP-Finance at Eidos Therapeutics, Inc. from 2020 to 2021, and a Senior Vice President-Finance at Graphite Bio, Inc. Mr. Valle also worked as a Senior Accounting Officer at Pharmacyclics, Inc. from 2012 to 2015.
Mr. Valle obtained his undergraduate degree from San Jose State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOMEA FUSION INC
0.12% | 11/06/2024 | 42,500 ( 0.12% ) | 447 100 $ | 31/05/2024 |
Franco Valle active positions
| Companies | Position | Start |
|---|---|---|
| BIOMEA FUSION, INC. | Director of Finance/CFO | 26/07/2021 |
Former positions of Franco Valle
| Companies | Position | End |
|---|---|---|
| EIDOS THERAPEUTICS, INC. | Director of Finance/CFO | 01/04/2021 |
| IOVANCE BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 14/08/2017 |
Pharmacyclics, Inc.
 Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Comptroller/Controller/Auditor | 01/05/2015 |
| PHARMACYCLICS, INC. | Comptroller/Controller/Auditor | - |
| LENZ THERAPEUTICS, INC. | Director of Finance/CFO | - |
Training of Franco Valle
| San Jose State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| BIOMEA FUSION, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Pharmacyclics, Inc.
Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Health Technology |
- Stock Market
- Insiders
- Franco Valle
